Uncontrolled pain remains a major clinical challenge in the management of knee osteoarthritis (OA), the most common disabling joint disease. Worse pain is associated with synovial innate immune cell infiltration (synovitis), but the role of innate immune regulatory cells in pain is unknown. Our objective was to identify synovial innate immune cell subsets and pathophysiologic mechanisms associated

ObjectivesEndogenous retroelements (EREs) stimulate type 1 interferon (IFN‐I) production but have not been explored as potential interferonogenic triggers in Rheumatoid Arthritis (RA). We investigated ERE expression in early RA (eRA), a period where IFN‐I is increased.MethodsERE expression (LTR5, LINE1, SINE) in disease modifying treatment naïve eRA whole blood and bulk synovial tissue was examined

Idiopathic inflammatory myopathies (myositis, IIMs) are rare, systemic autoimmune disorders that lead to muscle inflammation, weakness, and extra-muscular manifestations, with a strong genetic component influencing disease development and progression. Previous genome-wide association studies identified loci associated with IIMs. In this study, we imputed data from two prior genome-wide myositis studies

ObjectiveAn increased risk of primary biliary cholangitis (PBC) has been reported in patients with systemic sclerosis (SSc). Our study aims to investigate the shared genetic susceptibility between the two disorders and to define candidate causal genes using cross‐phenotype GWAS meta‐analysis.MethodsWe performed cross‐phenotype GWAS meta‐analysis and Bayesian colocalization analysis for SSc and PBC

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

ObjectiveIn rheumatoid arthritis (RA) and spondyloarthritis (SpA), managing persistent pain remains challenging. Little is known regarding impaired pain pathways in these patients and the impact of bDMARDs. The objective of the RAPID (Rheumatism Pain Inhibitory Descending pathways) study was to assess pain thresholds and descending pain modulation in patients with active RA or SpA following introduction

ObjectivePeople with axial spondyloarthritis (axSpA) have increased fracture risk relative to the general population, possibly related to chronic inflammation. We assessed the impact of treatment with tumor necrosis factor inhibitors (TNFi) and non‐biologic conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) on hip and spine fractures in axSpA, relative to nonsteroidal anti‐inflammatory

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

ObjectiveA phase II trial tested different doses of the anti‐CD40 monoclonal antibody BI655064 as add‐on therapy to the standard of care in class III or IV Lupus Nephritis (LN) patients with active disease. A post‐hoc analysis showed a potential benefit of the higher tested doses (180mg/240mg) versus low dose (120mg)/placebo. We investigated whether the treatment effect of BI655064 on kidney outcomes

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

ObjectiveTwo randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSC) compared to monthly cyclophosphamide. We asked if an unmodified PBSC graft followed by maintenance mycophenolate mofetil (MMF)

Background/Statement of PurposeSyndrome of Undifferentiated Recurrent Fevers (SURF) is characterized by recurrent fevers and autoinflammation without a confirmed molecular diagnosis of a Hereditary Recurrent Fever syndrome (HRF), and not fulfilling criteria for Periodic Fever, Adenitis, Pharyngitis, Aphthous stomatitis syndrome (PFAPA). The goal of this study was to characterize clinical features of

Click on the article title to read more.

Click on the article title to read more.

ObjectiveTo evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks.MethodsIn this randomised, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (125 mg weekly) + SOC (abatacept group) or placebo + SOC (placebo group) (NCT02971683)

ObjectiveThe DRB1 locus is strongly associated with both susceptibility and resistance to rheumatoid arthritis (RA). DRB1 alleles encoding the VKA or VRA epitope in positions 11, 71 and 74 confer the highest risk of developing RA, while the allele encoding VEA is protective. We therefore investigated the feasibility of creating antigen‐specific tolerance without inducing alloreactivity by replacing

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

ObjectiveTo report 52‐week safety and efficacy of ianalumab from phase 2b dose‐finding study in patients with Sjögren's disease (SjD).MethodsPatients randomly received (1:1:1:1) ianalumab (5, 50, or 300 mg) or placebo subcutaneously every 4 weeks till week 24 (treatment period [TP]1). At week 24, patients on 300 mg were re‐randomized to continue 300 mg or receive placebo till week 52 (TP2), patients

Click on the article title to read more.

Click on the article title to read more.

Interstitial lung disease (ILD) is a common and potentially lethal complication of systemic sclerosis (SSc). Screening by HRCT is recommended in all patients with risk factors, including early disease. Little is known on late presentations of ILD. This study aimed to characterize the incidence, risk factors and outcomes of late-onset SSc-ILD.

Adult-onset Still disease (AOSD) is a systemic autoinflammatory disorder (AID) of unknown etiology. Genetic studies have been limited. Here, we conducted detailed genetic and inflammatory biomarker analysis of a large cohort with AOSD to investigate the underlying pathology and identify novel targets for potential treatment.

Click on the article title to read more.

Click on the article title to read more.

Macrophage activation syndrome (MAS) is a state of immune hyperactivation that can result in life-threatening multisystem end-organ dysfunction. Often termed a “cytokine storm,” MAS occurs among the rheumatic diseases most typically in Still's disease but also in systemic lupus erythematosus and Kawasaki disease. MAS can also accompany infection, malignancy, and inborn errors of immunity. This review

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

The objective of this study is to describe recent trends in disease-modifying antirheumatic drug (DMARD) use for children with juvenile idiopathic arthritis (JIA) in the United States.

The patient, a 60-year-old woman with osteoporosis, complained of pain in the right ankle, which spread to the perimalleolar region, and then the left ankle. No fractures were detected on the radiograph; magnetic resonance (MR) imaging showed bone edema in the cuboid–calcaneal bone heads and the left distal metadiaphyseal tibia. The patient received nonsteroidal anti-inflammatory drugs, analgesics

Patients with systemic lupus erythematosus (SLE) were excluded from sodium–glucose cotransporter 2 inhibitors (SGLT2i) clinical trials. It is unknown whether the cardiorenal benefits of SGLT2i extend to patients with SLE and comorbid type 2 diabetes (T2D).